CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 17 enrolled
Drug / intervention
Estrogendrug
Likely dose
Estrogen 0.625 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00229450
NCT00229450Phase 4Completed
CompareCT.gov

Dose Response Effects of Estrogen Augmentation in Mood & Memory in Perimenopausal Depression

University of California, Los Angeles·interventional·Posted Sep 29, 2005·Updated Feb 25, 2020

In Brief

A Phase 4 clinical trial evaluating Estrogen for Depressive Disorder, Major and Menopause. Completed, enrolled 17 participants across 1 site.

Detailed Summary

During perimenopause (the time just prior to menopause), women often notice many biological, psychological, and social changes. In particular, some women experience depressive symptoms during perimenopause that are severe enough to warrant antidepressant medication. Whether or not women with perimenopausal depression respond to antidepressant medication may depend on the level of estrogen in their blood. This study will investigate whether estrogen will help women who only partially respond to antidepressant medications, as well as examine how different doses of estrogen may affect individuals differently.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major, Menopause
CountriesUnited States
CollaboratorsNational Alliance for Research on Schizophrenia and Depression

Timeline

Phase 4CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 29, 2005
Enrollment StartApr 1, 2002
Primary CompletionAug 1, 2003
Study CompletionAug 1, 2004
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.8 years ago

Interventions

Estrogendrug

0.625 mg/day of conjugated Estrogen